|Other names||D-16726; NSC-341952|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||351.402 g·mol−1|
|3D model (JSmol)|
Zindoxifene (INN; former developmental code names D-16726, NSC-341952) is a nonsteroidal selective estrogen receptor modulator (SERM) that was under development in the 1980s and early 1990s for the treatment of breast cancer but was not marketed. It showed estrogenic-like activity in preclinical studies and failed to demonstrate effectiveness as a treatment for breast cancer in clinical trials. Zindoxifene was the lead compound of the distinct 2-phenylindole class of SERMs, and the marketed SERM bazedoxifene was derived from the major active metabolite of zindoxifene, D-15414. Zindoxifene was first described in 1984.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|